Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEMADEX vs EVZIO (AUTOINJECTOR)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Competitive antagonist at mu-opioid receptors, reversing opioid-induced respiratory depression and other central nervous system depressant effects.
Edema associated with heart failure, hepatic cirrhosis, and renal disease,Hypertension (off-label)
Emergency treatment of known or suspected opioid overdose, manifested by respiratory and/or central nervous system depression
Oral: 5-10 mg once daily; may increase to 20 mg once daily if needed. IV: 5-10 mg once daily; may increase to 20 mg once daily if needed. Maximum dose: 40 mg/day.
Adults: 2 mg intramuscularly or subcutaneously into the anterolateral thigh, repeat every 2-3 minutes as needed until emergency medical assistance arrives.
The terminal elimination half-life is approximately 4 hours (range 2-8 hours) in patients with normal renal function. In renal impairment (creatinine clearance <30 m L/min), half-life is prolonged to 10-12 hours due to reduced renal clearance. In hepatic cirrhosis, half-life may be extended to 8-9 hours due to decreased metabolism.
Terminal elimination half-life of naloxone is approximately 1–2 hours in adults. The short half-life results in a duration of action that may be shorter than that of the opioid (e.g., fentanyl, methadone), necessitating repeated doses or continuous infusion. In neonates, half-life is prolonged (3–4 hours).
Primarily hepatic via CYP450 enzymes, with minimal renal clearance.
Primarily hepatic via glucuronidation; minor pathways include N-dealkylation. CYP450 involvement is minimal.
Approximately 50% of the absorbed dose is excreted unchanged in the urine via glomerular filtration and active tubular secretion. The remainder undergoes hepatic metabolism to glucuronide conjugates and minor oxidative metabolites, with biliary excretion of metabolites (about 30-40% of the dose) eliminated in feces. Renal clearance is the primary route for the parent drug.
Naloxone is primarily metabolized in the liver via glucuronidation, with minor contributions from N-dealkylation. The metabolites (naloxone-3-glucuronide) and parent drug are excreted renally. Approximately 50% of a dose is excreted in urine as naloxone-3-glucuronide, 25% as unchanged naloxone (after IV), and <5% in feces. Biliary excretion is minimal (<1%).
Torsemide (DEMADEX) is extensively bound to plasma proteins, primarily albumin, with a protein binding of >99%.
Approximately 45% bound to plasma proteins, primarily albumin.
The apparent volume of distribution (Vd) is approximately 0.16 L/kg (range 0.12–0.20 L/kg), indicating distribution primarily within extracellular fluid. Vd is increased in conditions with expanded extracellular volume (e.g., heart failure, cirrhosis, nephrotic syndrome).
2–3 L/kg in adults. The large Vd indicates extensive tissue distribution, including crossing the blood-brain barrier rapidly to reverse central opioid effects. In neonates, Vd is higher (3–5 L/kg).
Oral bioavailability is approximately 80–90%, with minimal first-pass metabolism. Absorption is rapid and not significantly affected by food.
Intramuscular or subcutaneous: approximately 60–80% relative to IV (with the autoinjector delivering 0.4 mg or 2 mg doses). Oral bioavailability is <2% due to extensive first-pass metabolism, making oral administration ineffective for opioid reversal; thus, the autoinjector is for IM/SC use only.
GFR <20 m L/min/1.73 m²: Use with caution; may require dose reduction or discontinuation due to accumulation. GFR 20-50: No adjustment needed. GFR >50: No adjustment.
No dose adjustment required for renal impairment.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% or extend interval. Child-Pugh C: Avoid use or reduce dose by 75%.
No dose adjustment required for hepatic impairment.
Neonates and infants: 0.1-0.2 mg/kg/dose IV/IM once daily. Children: Oral: 0.5-1 mg/kg once daily; IV/IM: 0.1-0.2 mg/kg/dose once daily. Maximum: 5 mg/day.
Weight-based dosing: For children weighing <20 kg, 0.1 mg/kg intramuscularly or subcutaneously; for ≥20 kg, 2 mg intramuscularly or subcutaneously. Repeat every 2-3 minutes as needed.
Start at lower end of dose range (2.5-5 mg orally once daily); titrate slowly due to increased sensitivity and renal impairment risk.
No specific dose adjustment needed; use caution due to potential comorbidities.
None.
None.
Hypotension and volume depletion,Electrolyte imbalances (hypokalemia, hyponatremia, hypochloremia),Ototoxicity (especially with rapid IV administration or high doses),Hyperuricemia,Sulfonamide allergy cross-reactivity
Risk of acute withdrawal syndrome in opioid-dependent patients.,May precipitate severe withdrawal in neonates if used during pregnancy.,Limited efficacy against buprenorphine or partial agonists; higher or repeat doses may be needed.,Monitor for recurrence of respiratory depression due to short duration of action relative to some opioids.,Not a substitute for emergency medical care.
Anuria,Severe electrolyte depletion,Hypersensitivity to sulfonamides or bumetanide (Demadex is a sulfonamide derivative)
Hypersensitivity to naloxone or any component of the autoinjector.
Avoid excessive licorice intake (glycyrrhizin) as it can exacerbate hypokalemia. Limit sodium-rich foods (processed foods, canned soups) to enhance diuretic effect and control edema. Increase potassium-rich foods (bananas, oranges, potatoes) unless on a potassium-sparing medication. Avoid grapefruit juice as it may affect metabolism.
No known food interactions with naloxone. No dietary restrictions required.
DEMADEX (torsemide) is a loop diuretic. Human data are limited. In animal studies, high doses caused fetal resorptions and maternal toxicity. First trimester: insufficient human data; avoid unless benefit outweighs risk. Second/third trimester: risk of fetal oligohydramnios, renal impairment, and hypovolemia; use only if clearly needed.
Naloxone crosses the placenta. First trimester: No evidence of teratogenicity in animal studies at doses up to 100 mg/kg/day (SC). Second/third trimester: No known risk of fetal malformations; may precipitate withdrawal in opioid-dependent fetuses, potentially causing fetal distress or preterm labor.
Torsemide is excreted in breast milk in small amounts; M/P ratio not reported. Due to potential for diuresis, electrolyte imbalance, and allergic reactions in the infant, caution is recommended. Alternative diuretics with more safety data are preferred.
Naloxone is excreted in breast milk in trace amounts; no adverse effects reported in nursing infants. M/P ratio not available.
Dosing may need adjustment due to increased plasma volume and GFR in pregnancy. Start at lowest effective dose. Monitor diuretic response and electrolyte balance; dose titration may be required. Postpartum, drug elimination may return to prepregnancy kinetics.
No pharmacokinetic data indicate dose adjustments; use same dose as non-pregnant adults. Reversal of opioid effects may precipitate withdrawal; monitor closely.
DEMADEX (torsemide) is a loop diuretic with high bioavailability (80-100%) and a longer half-life (3-4 hours) than furosemide, allowing once-daily dosing. It is primarily metabolized by CYP2C9, so caution is needed with CYP2C9 inhibitors like amiodarone. Monitor for ototoxicity at high doses or rapid infusion. Hypokalemia risk persists; consider potassium supplementation or aldosterone antagonist. Use cautiously in sulfonamide allergy due to potential cross-sensitivity.
EVZIO is a naloxone auto-injector for emergency treatment of opioid overdose. Administer intramuscularly or subcutaneously into anterolateral thigh (through clothing if necessary). Each device delivers a single 2 mg dose. After use, seek immediate medical attention due to short half-life (30-81 min) relative to opioids; repeated doses may be needed. Monitor for opioid withdrawal syndrome, especially in physically dependent patients. Store at 20-25°C (68-77°F), excursions permitted to 15-30°C (59-86°F). Do not remove the auto-injector from its case until ready to use.
Take DEMADEX exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Weigh yourself daily and report sudden weight gain or loss of more than 2-3 pounds in a day.,Avoid alcohol and beverages containing caffeine as they may increase dehydration.,Do not take DEMADEX with licorice (which can worsen hypokalemia) or with high-sodium antacids.,Report signs of hearing loss, ringing in the ears, dizziness, or muscle cramps immediately.,Stand up slowly to prevent dizziness from low blood pressure.,Monitor for signs of dehydration: dry mouth, thirst, infrequent urination.
Inject EVZIO into the outer thigh, through clothing if needed, as soon as overdose is suspected.,After injecting, call 911 or seek emergency medical help immediately.,The effect of EVZIO lasts only 30-90 minutes; opioids may last longer, so repeated doses might be necessary.,Family and caregivers should receive training on recognizing overdose signs (unconsciousness, slow breathing, pinpoint pupils) and using EVZIO.,Store EVZIO in its case at room temperature, away from light and moisture; do not refrigerate or freeze.,Check expiration date regularly and replace before expiry; training devices are for practice only.,An overdose may cause withdrawal symptoms such as nausea, vomiting, sweating, rapid heart rate, or agitation.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEMADEX vs EVZIO (AUTOINJECTOR), answered by our medical review team.
DEMADEX is a Loop Diuretic that works by Inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. EVZIO (AUTOINJECTOR) is a Opioid Antagonist that works by Competitive antagonist at mu-opioid receptors, reversing opioid-induced respiratory depression and other central nervous system depressant effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEMADEX and EVZIO (AUTOINJECTOR) depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEMADEX is: Oral: 5-10 mg once daily; may increase to 20 mg once daily if needed. IV: 5-10 mg once daily; may increase to 20 mg once daily if needed. Maximum dose: 40 mg/day.. The standard adult dose of EVZIO (AUTOINJECTOR) is: Adults: 2 mg intramuscularly or subcutaneously into the anterolateral thigh, repeat every 2-3 minutes as needed until emergency medical assistance arrives.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEMADEX and EVZIO (AUTOINJECTOR) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEMADEX is classified as Category C. DEMADEX (torsemide) is a loop diuretic. Human data are limited. In animal studies, high doses caused fetal resorptions and maternal toxicity. First trimester: insufficient human da. EVZIO (AUTOINJECTOR) is classified as Category C. Naloxone crosses the placenta. First trimester: No evidence of teratogenicity in animal studies at doses up to 100 mg/kg/day (SC). Second/third trimester: No known risk of fetal ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.